Genomic Changes in Childhood Acute Lymphoblastic Leukemia

The recruitment status of this study is unknown because the information has not been verified recently.
Verified March 2010 by National Taiwan University Hospital.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT01089907
First received: March 17, 2010
Last updated: March 18, 2010
Last verified: March 2010

March 17, 2010
March 18, 2010
April 2010
January 2013   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT01089907 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Genomic Changes in Childhood Acute Lymphoblastic Leukemia
Genomics Evolution in Childhood Acute Lymphoblastic Leukemia

To study the genomics with cell cycle and lymphocyte differentiation in disease, remission and relapse of childhood acute lymphoblastic leukemia. Then correlate these data with age, white cell count, cytogenetic changes, response to the chemotherapy and prognosis.

In order to know the genomic evolution of childhood acute lymphoblastic leukemia, we will collect bone marrow (10c.c.) at diagnosis, remission and relapse. We will do the following genes in addition to gene-chip including IKZF1,ETV6, EBF1, NR3C1, RAG1/G2, TCF3, BTLA, PAX5,LEF1, ERG and VPREB1.We will study the gene dosages and degree of methylation. The estimated patients numbers will be 300-400. Then we will correlate these data with patients'age, white blood cell count at diagnosis, cytogenetic abnormalities, response to the chemotherapy and prognosis.

Observational
Observational Model: Case-Only
Time Perspective: Retrospective
Not Provided
Retention:   Samples With DNA
Description:

bone marrow, peripheral blood

Non-Probability Sample

Acute lymphoblastic leukemia patients under 18 years of age

Acute Lymphoblastic Leukemia
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
400
June 2013
January 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. patients diagnosed as acute lymphoblastic leukemia
  2. age less than or equal to 18 years old
  3. signed informed consent

Exclusion Criteria:

  1. who is not acute lymphoblastic leukemia
  2. who did not sign informed consent
Both
up to 18 Years
No
Contact: Dong-Tsamn Lin, M.D. 02-23123456 ext 65399 dtlin@ntuh.gov.tw
Contact: young-li Yang, M.D. 02-23123456 ext 71311 yangylmd@gmail.com
Taiwan
 
NCT01089907
200906028R
Yes
Lin Dong-Tsamn, National Taiwan University Hospital
National Taiwan University Hospital
Not Provided
Principal Investigator: Dong-Tsamn Lin, M.D. National Taiwan University Hospital,Taipei,Taiwan
National Taiwan University Hospital
March 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP